Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA ...

Researchers sought to assess the risk of developing ALL in patients with multiple myeloma treated with lenalidomide.

Am J Health Syst Pharm. 2007;64(17):1799-1807. Despite a similar chemical structure to thalidomide, the toxicity profile of lenalidomide has been shown to be quite different. The major dose ...

Lenalidomide, an analog of thalidomide, was developed because of its more potent anti-MM activity and better toxicity profile than the parent compound. Since its introduction in 2004, lenalidomide ...

Daratumumab therapy resulted in superior progression-free survival in frail patients with previously untreated multiple myeloma.

DARZALEX FASPRO ® is a prescription medicine used to treat adult patients with multiple myeloma: · in combination with the medicines bortezomib, lenalidomide, and dexamethasone in newly ...

Daratumumab, hyaluronidase-fihj; 1800mg/30000units; per vial; soln for SC inj; preservative-free. Daratumumab binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing ...

Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory ...

DARZALEX FASPRO ® is a prescription medicine used to treat adult patients with multiple myeloma: · in combination with the medicines bortezomib, lenalidomide, and dexamethasone in newly ...

Opens in a new tab or window SAN DIEGO -- Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide (Revlimid) and rituximab (Rituxan) resulted in ...